Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents [clinicaltrials:NCT02264678]

Bio2RDF identifier

NCT02264678

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02264678

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT02264678

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

114

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT02264678 arm group 841f9c6750a0cbaa28dcceeaff197733 [clinicaltrials_resource:NCT02264678/arm-group/841f9c6750a0cbaa28dcceeaff197733]

NCT02264678 arm group fae35184cc9121db497af2423562ef05 [clinicaltrials_resource:NCT02264678/arm-group/fae35184cc9121db497af2423562ef05]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

This is a modular, phas ...... s AZD6738 with Olaparib

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Ascending Doses of AZD6738 in ...... nd/or Novel Anti Cancer Agents

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:1477cb27a5da9c031ed73b95c93ef569]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:0252808f8117bbe7b24601c5622f36c3]

Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:09ded4cdb80266512c17931a0ba1bce4]

Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:0af8874fb3f81ed440fed08244a2f566]

Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:0ba98b599a2f5cb38ca21bc2a287a9bb]

Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:10251a4b4c602f82fdc420ae4525f6a9]

Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:11712af29e69918b8801a9031530e1f6]

Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:18657d81106726adeb5f4b805a567c24]

Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:18c02296410fd55132583995016a6089]

Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:18c6e1eca20ac9e3e93de1d93088e356]

Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:1c5f8f8bb8aaccdb17af209688a67457]

completion date [clinicaltrials_vocabulary:completion-date]

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

This is a modular, phas ...... drug pharmacokinetics.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02264678 [clinicaltrials_resource:abc7f5c382fd643a9f28788b87b3e0dd]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2014-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Administration of AZD6738 in combination with carboplatin [clinicaltrials_resource:0961f7fac2b27d6721bdc60633516121]

Administration of AZD6738 in combination with olaparib [clinicaltrials_resource:483ba04cce1b799f9885cb3b3533a01c]

Administration of AZD6738 [clinicaltrials_resource:928462cc37c06047f3f3743df7ee3519]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Antineoplastic Agents [clinicaltrials_resource:0004b8f693c96d681b7cb3cf9683c0fd]

Carboplatin [clinicaltrials_resource:b23f008a3e6b2c8b098db9c0c9a2a2a6]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

ATM deficient

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

AstraZeneca [clinicaltrials_resource:a083735aebc9a325683091959d090667]

location [clinicaltrials_vocabulary:location]

Research Site [clinicaltrials_resource:d3b83a2f047e1cec01b84754d8ef6a1d]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02264678

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Modular Phase I, Open-Label, ...... th Advanced Solid Malignancies

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

D5330C00004

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

AstraZeneca Clinical Study Information Center [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]

overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]

AstraZeneca Clinical Study Information Center [clinicaltrials_resource:26d9d655823d04e77ff0368b4c5c6d08]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:1f28c0594210e70c3e0f2d6132bf4619]

phase [clinicaltrials_vocabulary:phase]

Phase 1/Phase 2 [clinicaltrials_resource:72d8d9eabd48f679d5dffa41c4dd93f7]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

AstraZeneca [clinicaltrials_resource:a083735aebc9a325683091959d090667]

start date [clinicaltrials_vocabulary:start-date]

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02264678 study design [clinicaltrials_resource:5ff89dfb7c811939696c5c5c4cf3ee2a]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02264678

verification date [clinicaltrials_vocabulary:verification-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02264678

http://www.w3.org/2001/XMLSchema#string

title

Ascending Doses of AZD6738 in ...... nd/or Novel Anti Cancer Agents

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]